214760-18-6

Basic information

• Product Name: Benzonitrile, 4-acetyl-2-fluoro- (9CI)
• Synonyms: Benzonitrile, 4-acetyl-2-fluoro- (9CI);4-ACETYL-2-FLUOROBENZONITRILE;Benzonitrile,4-acetyl-2-fluoro-;4'-Cyano-3'-fluoroacetophenone
• CAS NO: 214760-18-6
• Molecular Formula: C₉H₆FNO
• Molecular Weight: 163.1484432
• Product Categories: HALIDE;ACETYLGROUP
• Mol File: 214760-18-6.mol

Chemical Properties

• Boiling Point: 296.2±25.0 °C(Predicted)
• Appearance: /
• Density: 1.21±0.1 g/cm3(Predicted)
• CAS DataBase Reference: Benzonitrile, 4-acetyl-2-fluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 4-acetyl-2-fluoro- (9CI)(214760-18-6)
• EPA Substance Registry System: Benzonitrile, 4-acetyl-2-fluoro- (9CI)(214760-18-6)

Safety Data

• Hazardous Substances Data: 214760-18-6(Hazardous Substances Data)

Usage

Uses

Unfortunately, the provided materials do not contain any information about the specific uses of Benzonitrile, 4-acetyl-2-fluoro(9CI). Therefore, it is not possible to list its applications and reasons for use in different industries based on the given information.

Upstream product

• 97674-02-7 tributyl(1-ethoxyvinyl)stannane 
• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 176508-81-9 4-cyano-3-fluorobenzoic acid 
• 695188-21-7 4-bromo-3-fluorobenzoyl chloride 
• 153556-42-4 4-bromo-3-fluorobenzoic acid 
• 343564-56-7 4-bromo-3-fluoro-N-methoxy-N-methyl-benzamide 
• 75-16-1 methylmagnesium bromide 
• 521093-90-3 (4-cyano-3-fluorophenyl)zinc(II) bromide 
• 75-36-5 acetyl chloride 
• 304445-49-6 1-(4-bromo-3-fluorophenyl)ethan-1-one 
• 557-21-1 dicyanozinc 
• 1201803-19-1 C₁₁H₁₀FNO 

Downstream Products

• 1029714-95-1 4-acetyl-2-fluorobenzoic acid 
• 1007315-24-3 2-fluoro-4-{2-[(2-hydroxy-1,1-dimethylethyl)amino]-1,3-thiazol-4-yl}benzonitrile 
• 1403670-38-1 C₂₅H₂₆ClN₃O₅ 
• 1403670-39-2 C₂₅H₂₆ClN₃O₅ 
• 440105-59-9 2-fluoro-4-(1-hydroxyethyl)benzonitrile 
• 366790-50-3 4-(2-bromoacetyl)-2-fluorobenzonitrile 

Relevant articles and documents

NOVEL BENZIMIDAMIDES COMPOUNDS COMPRISING AN OXABORININ RING

The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)benzimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea, atopic dermatitis, psoriasis and itch) cau

THIAZALOPYRROLIDINE INHIBITORS OF ROR-GAMMA

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Discovery of selective and potent inhibitors of gram-positive bacterial thymidylate kinase (TMK)

Thymidylate kinase (TMK) is an essential enzyme in bacterial DNA synthesis. The deoxythymidine monophosphate (dTMP) substrate binding pocket was targeted in a rational-design, structure-supported effort, yielding a unique series of antibacterial agents sh

IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH

The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

Pyrrolidine and related derivatives useful as PR modulators

Compounds of the following structure are described: wherein R1-R6, R11, R12, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compou

Tricyclic oxazolidone derivatives useful as PR modulators

Compounds of the following structure are described: wherein R1-R6, R16, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are use

Oxazolidone derivatives as PR modulators

Compounds of the following structure are described: wherein R1, R2, R5, R6, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

Imidazolidin-2-one derivatives useful as PR modulators

Compounds of the following structure are described: wherein R1-R6, R10, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful f

Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of Formula (1.0.0): 1 wherein R5 and R6 are